5 351

Cited 5 times in

Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy

DC Field Value Language
dc.contributor.author김원주-
dc.contributor.author이병인-
dc.contributor.author허경-
dc.date.accessioned2015-04-23T16:52:48Z-
dc.date.available2015-04-23T16:52:48Z-
dc.date.issued2010-
dc.identifier.issn1059-1311-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101402-
dc.description.abstractWe assessed the clinical variables predicting the feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Thirty patients aged 15 years or older with refractory partial epilepsy, who had been treated with slow-release carbamazepine as monotherapy or in combination therapy, were switched overnight from slow-release carbamazepine (mean dose at switching, 900 mg/day) to oxcarbazepine. Of these 30 patients, 29 (96.7%) had been treated with a slow-release formulation of carbamazepine. The proportion of patients with polytherapy was 85.3%. Overall, 9 of 30 (30%) switched patients experienced clinically significant adverse events until 2 weeks after switching, including 2 with seizure aggravation. The only clinical variable related to the failure of overnight switching was the number of seizures at baseline-
dc.description.statementOfResponsibilityopen-
dc.format.extent356~358-
dc.relation.isPartOfSEIZURE-EUROPEAN JOURNAL OF EPILEPSY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAnticonvulsants/administration & dosage-
dc.subject.MESHAnticonvulsants/adverse effects-
dc.subject.MESHAnticonvulsants/therapeutic use*-
dc.subject.MESHCarbamazepine/administration & dosage-
dc.subject.MESHCarbamazepine/adverse effects-
dc.subject.MESHCarbamazepine/analogs & derivatives*-
dc.subject.MESHCarbamazepine/therapeutic use-
dc.subject.MESHDelayed-Action Preparations-
dc.subject.MESHDrug Resistance-
dc.subject.MESHEpilepsies, Partial/drug therapy*-
dc.subject.MESHFemale-
dc.subject.MESHForecasting-
dc.subject.MESHHumans-
dc.subject.MESHKorea-
dc.subject.MESHMale-
dc.subject.MESHSeizures/epidemiology-
dc.subject.MESHSeizures/prevention & control-
dc.subject.MESHTreatment Failure-
dc.titleClinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학)-
dc.contributor.googleauthorSang-Ahm Lee-
dc.contributor.googleauthorKyoung Heo-
dc.contributor.googleauthorWon-Joo Kim-
dc.contributor.googleauthorHong-Ki Song-
dc.contributor.googleauthorSung-Eun Kim-
dc.contributor.googleauthorSang-Ho Kim-
dc.contributor.googleauthorSoon-Kee No-
dc.contributor.googleauthorByung-In Lee-
dc.identifier.doi10.1016/j.seizure.2010.05.002-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00771-
dc.contributor.localIdA02797-
dc.contributor.localIdA04341-
dc.relation.journalcodeJ02648-
dc.identifier.eissn1532-2688-
dc.identifier.pmid20538492-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S1059131110001068-
dc.subject.keywordCarbamazepine-
dc.subject.keywordOxcarbazepine-
dc.subject.keywordSwitching-
dc.subject.keywordPartial epilepsy-
dc.contributor.alternativeNameKim, Won Joo-
dc.contributor.alternativeNameLee, Byung In-
dc.contributor.alternativeNameHeo, Kyoung-
dc.contributor.affiliatedAuthorKim, Won Joo-
dc.contributor.affiliatedAuthorLee, Byung In-
dc.contributor.affiliatedAuthorHeo, Kyoung-
dc.citation.volume19-
dc.citation.number6-
dc.citation.startPage356-
dc.citation.endPage358-
dc.identifier.bibliographicCitationSEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.19(6) : 356-358, 2010-
dc.identifier.rimsid51032-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.